HLA-A and hepatocellular carcinoma: Seventeen HLA-A*24:02-, 02:01-, or 02:06-matched patients (six with CRC, five with EC, four with HCC, and one each with PDAC and Gastric cancer) comprised the study population and received vaccination therapy (73% of the enrolled populations).